Showing results (1-10 of 651) with videos related to
Sort By:
Pageof 66
Cancer|July 19, 2011
Spleen deflation and beyond: the pros and cons of Janus kinase 2 inhibitor therapy for patients with myeloproliferative neoplasmsAlfonso Quintás-Cardama, Srdan VerstovsekClinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 15, 2013
Molecular pathways: Jak/STAT pathway: mutations, inhibitors, and resistanceAlfonso Quintás-Cardama, Srdan VerstovsekExpert Opinion on Investigational Drugs|April 28, 2011
New JAK2 inhibitors for myeloproliferative neoplasmsAlfonso Quintás-Cardama, Srdan VerstovsekCancer|June 22, 2011
Advances and controversies in the diagnosis, pathogenesis, and treatment of systemic mastocytosisAlfonso Quintás-Cardama, Nitin Jain, Srdan VerstovsekCurrent Hematologic Malignancy Reports|April 29, 2010
Conventional and experimental drug therapy in myelofibrosis with myeloid metaplasiaRuben A Mesa, Alfonso Quintás-Cardama, Srdan VerstovsekExpert Opinion on Investigational Drugs|November 17, 2006
Experimental therapy in myelofibrosis with myeloid metaplasiaSrdan Verstovsek, Alfonso Quintás-Cardama, Hagop Kantarjian, et al.Nature Reviews. Drug Discovery|February 2, 2011
Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyondAlfonso Quintás-Cardama, Hagop Kantarjian, Jorge Cortes, et al.Seminars in Thrombosis and Hemostasis|July 1, 2006
Pegylated interferon therapy for patients with Philadelphia chromosome-negative myeloproliferative disordersAlfonso Quintás-Cardama, Hagop M Kantarjian, Francis Giles, et al.Leukemia & Lymphoma|January 3, 2013
Bone marrow mast cell burden and serum tryptase level as markers of response in patients with systemic mastocytosisAlfonso Quintás-Cardama, Matjaz Sever, Jorge Cortes, et al.Clinical Lymphoma, Myeloma & Leukemia|February 9, 2013
Prognostic model to identify patients with myelofibrosis at the highest risk of transformation to acute myeloid leukemiaAlfonso Quintás-Cardama, Hagop Kantarjian, Sherry Pierce, et al.Pageof 66